尔康制药(300267) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥395,206,072.29, a decrease of 11.55% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of ¥11,876,663.64, representing a decline of 290.80% year-on-year[4] - The basic earnings per share for Q3 2023 was -¥0.0058, down 293.33% from the previous year[4] - Total operating revenue for Q3 2023 reached CNY 1,445,366,591.95, an increase of 9.7% compared to CNY 1,317,388,175.56 in the same period last year[20] - Net profit for Q3 2023 was CNY 23,962,311.35, a decrease of 20.5% from CNY 30,294,249.44 in Q3 2022[21] - The company reported a profit before tax of CNY 41,306,414.75, down from CNY 49,091,648.83, indicating a decline of 16.5% year-over-year[21] - Other comprehensive income after tax for Q3 2023 was CNY 53,865,324.86, down from CNY 182,718,966.97, a decrease of 70.5%[21] - The company reported a total comprehensive income of CNY 77,827,636.21, significantly lower than CNY 213,013,216.41 in the same quarter last year, a decline of 63.5%[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,524,396,567.87, a decrease of 5.66% from the end of the previous year[4] - As of September 30, 2023, the total current assets decreased to CNY 1,694,957,760.50 from CNY 2,091,204,367.56 at the beginning of the year, representing a decline of approximately 19%[17] - Total assets decreased to CNY 5,524,396,567.87 from CNY 5,855,659,382.96, a decline of 5.6%[19] - Total liabilities decreased to CNY 457,593,401.69 from CNY 804,568,205.38, a significant reduction of 43.2%[19] - The company's equity attributable to shareholders increased to CNY 5,082,273,045.39 from CNY 5,050,820,622.25, reflecting a slight increase of 0.6%[19] Cash Flow - The cash flow from operating activities showed a net outflow of ¥22,633,088.26, a decline of 115.44% compared to the same period last year[4] - Cash inflow from operating activities totaled ¥1,784,411,604.43, compared to ¥1,751,104,138.59 in the previous year, showing a slight increase[22] - Net cash flow from operating activities was negative at -¥22,633,088.26, a significant decline from a positive ¥146,603,775.86 in the same period last year[22] - Cash outflow from investing activities was ¥921,044,133.51, down from ¥1,541,502,268.40 in the previous year, indicating a reduction in investment spending[24] - Net cash flow from investing activities was -¥96,757,309.29, an improvement from -¥488,845,880.31 in Q3 2022[24] - Cash inflow from financing activities was ¥115,550,895.10, compared to ¥276,749,600.00 in the previous year, reflecting a decrease in financing received[24] - Net cash flow from financing activities was -¥236,070,256.85, a decline from a positive ¥11,612,877.84 in Q3 2022[24] - The ending balance of cash and cash equivalents was ¥275,147,122.98, down from ¥290,564,168.45 at the end of Q3 2022[24] - The company reported a total cash outflow of ¥357,793,276.38 for the quarter, compared to an outflow of ¥311,006,577.20 in the same period last year[24] Research and Development - The company has made progress in drug formulation research, achieving consistency evaluation for several products, which is expected to positively impact future sales[14] - The company applied for 2 new invention patents related to lithium carbonate and aminophylline during the third quarter[15] - The company is in the process of conducting bioequivalence trials for its heart failure drug formulations[15] - The company continues to focus on the integration of raw materials and formulations, utilizing biosynthesis technology for the development of biosimilars[15] Market and Operational Changes - The company reported a significant increase in prepayments by 79.12%, amounting to ¥15,105.16, due to expanded raw material procurement[8] - The company experienced a 31.72% increase in selling expenses, totaling ¥8,943.15, attributed to enhanced market expansion efforts for new auxiliary products[10] - Investment income increased by 542.67% to ¥1,898.82, primarily due to forward foreign exchange contract settlements[10] - The company reported a 102.80% increase in other current assets, reaching ¥15,098.29, due to an increase in bank wealth management products[8] - The company is actively expanding its lithium carbonate supply chain, establishing branches in Nigeria and other countries to enhance resource utilization[15] Shareholder Information - The total number of common stock shareholders as of the report date was 43,902[13] - The largest shareholder, Shuai Fangwen, holds a 41.38% stake, with a total of 853,574,906 shares, of which 640,181,179 shares are pledged[13] Audit Status - The third quarter report was not audited, indicating that the financial figures are subject to further verification[25]